secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-038033
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023
--------------------------------------------------------------------------------

- Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).
- Cash and equivalents $116.9M at June 30, 2023, funding operations into first half of 2025.
- MM-120 Phase 2b for GAD enrollment target lowered to 180 patients; topline results expected Q4 2023.
- MM-120 Phase 2a for ADHD over 80% enrolled; topline readout expected Q4 2023 / Q1 2024.
- Exclusive license agreement with Catalent for Zydis ODT formulation of MM-120 for pivotal trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/0000950170-23-038033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023038033/mnmd-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer